Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non–small-cell lung cancer
TG Karrison, ML Maitland, WM Stadler… - Journal of the National …, 2007 - academic.oup.com
Background The primary objective of phase II cancer clinical trials is to determine whether a
new regimen has sufficient activity to warrant further study, with activity generally defined as …
new regimen has sufficient activity to warrant further study, with activity generally defined as …
Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung …
TG Karrison, ML Maitland, WM Stadler… - Journal of the National …, 2007 - elibrary.ru
Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size:
Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer КОРЗИНА …
Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer КОРЗИНА …
[PDF][PDF] Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small-Cell …
TG Karrison, ML Maitland, WM Stadler, MJ Ratain - J Natl Cancer Inst, 2007 - Citeseer
Background The primary objective of phase II cancer clinical trials is to determine whether a
new regimen has sufficient activity to warrant further study, with activity generally defined as …
new regimen has sufficient activity to warrant further study, with activity generally defined as …
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
TG Karrison, ML Maitland, WM Stadler… - Journal of the National …, 2007 - europepmc.org
Background The primary objective of phase II cancer clinical trials is to determine whether a
new regimen has sufficient activity to warrant further study, with activity generally defined as …
new regimen has sufficient activity to warrant further study, with activity generally defined as …
Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non-Small-Cell Lung …
TG Karrison, ML Maitland… - JNCI: Journal of the …, 2007 - search.ebscohost.com
Background The primary objective of phase II cancer clinical trials is to determine whether a
new regimen has sufficient activity to warrant further study, with activity generally defined as …
new regimen has sufficient activity to warrant further study, with activity generally defined as …
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer
TG Karrison, ML Maitland… - Journal of the …, 2007 - pubmed.ncbi.nlm.nih.gov
Background The primary objective of phase II cancer clinical trials is to determine whether a
new regimen has sufficient activity to warrant further study, with activity generally defined as …
new regimen has sufficient activity to warrant further study, with activity generally defined as …
[引用][C] Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non-small-cell lung …
TG KARRISON, ML MAITLAND… - Journal of the …, 2007 - pascal-francis.inist.fr
Design of phase II cancer trials using a continuous endpoint of change in tumor size :
Application to a study of sorafenib and erlotinib in non-small-cell lung cancer CNRS Inist …
Application to a study of sorafenib and erlotinib in non-small-cell lung cancer CNRS Inist …